All In Biotech

Drug Trial Radar · NCT02091141

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Last checked: Nov 20, 2026Latest source record: Jul 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

673

Actual

Start

Apr 14, 2014

Primary completion

May 24, 2023

Study completion May 24, 2023

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Conditions

  • Neoplasms
  • Solid Tumors
  • Biliary Cancer
  • Salivary Cancer
  • Bladder Cancer

Interventions

  • TrastuzumabDrug

    Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • PertuzumabDrug

    Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • ErlotinibDrug

    Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • VemurafenibDrug

    Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • CobimetinibDrug

    Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • VismodegibDrug

    Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • AlectinibDrug

    Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

  • AtezolizumabDrug

    Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the InvestigatorTime frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
  2. Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • Western Regional Medical Center at Cancer Treatment Centers of America

    Goodyear, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • Science 37, Inc

    Culver City, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Moores UCSD Cancer Center; Dept Clinical Trials Office

    La Jolla, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Stanford Comprehensive Cancer Center

    Stanford, California

  • Kaiser Permanente - Vallejo

    Vallejo, California

  • University of Colorado

    Aurora, Colorado

  • SCRI Florida Cancer Specialists South

    Fort Myers, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch

    Orlando, Florida

  • Florida Cancer Specialist, North Region

    St. Petersburg, Florida

  • Florida Cancer Specialists, Research Department

    West Palm Beach, Florida

  • University Cancer & Blood Center, LLC; Research

    Athens, Georgia

  • Northeast Georgia Medical Center; Oncology Research Dept-5C

    Gainesville, Georgia

  • Southeastern Regional Medical Center, Inc.

    Newnan, Georgia

  • Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst

    Chicago, Illinois

  • University Of Chicago Medical Center; Section Of Hematology/Oncology

    Chicago, Illinois

  • Midwestern Regional Med Center

    Zion, Illinois

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Mayo Foundation

    Rochester, Minnesota

  • Research Medical Center - Antibiotic Research Associates, Inc.

    Kansas City, Missouri

  • Memorial Sloan Kettering - Monmouth

    Middletown, New Jersey

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment

    Albuquerque, New Mexico

  • University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment

    Albuquerque, New Mexico

  • University of New Mexico

    Albuquerque, New Mexico

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Memorial Sloan Kettering Cancer Center at Westchester

    Harrison, New York

  • Weill Cornell Univ Medical Ctr; Breast Cancer Center

    New York, New York

  • Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Univ No Carolina School of Med; Physicians Office Bldg

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest Univ Health Svcs; Internal Medicine

    Winston-Salem, North Carolina

  • Sanford Roger Maris Cancer Center

    Fargo, North Dakota

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.